MASSDEVICE ON CALL — CDC: Americans in Appalachia and the South are most sedentary. The Centers for Disease Control and Prevention released a report that says Americans in Alabama, Kentucky, Louisiana, Mississippi, Oklahoma and Tennessee are the least active, while people who live in Colorado, the west coast and parts of New England are the most active.
Business/Financial News
Wall Street Beat | Earnings Reports | Funding Roundup | Mergers & Acquisitions | Initial Public Offerings | Legal News
Medtronic “internal cast” effective on cancer patients’ spinal fractures | Research roundup
Here’s a roundup of recent clinical trial and scientific study news:
Paulson sells off 70 percent of Boston Scientific stake
One of Boston Scientific Corp.’s (NYSE:BSX) largest shareholders sold off nearly 70 percent of its stake in the medical device maker during the fourth quarter.
Paulson & Co. LLC now owns 25 million BSX shares, or about 1.5 percent of the Natick, Mass.-based firm. That position is worth $189.2 million, according to a regulatory filing.
For sale: One lab on a chip
In the market for a lab on a chip? Book your travel to New York for next month, when Able Signal Company LLC plans to put several micro-array and lab-on-a-chip patents on the auction block.
The five patents, all titled "Microarray detector and synthesizer," belong to University of Wisconsin-Madison researcher Perry Sandstrom and were granted between 2003 and 2009.
Boston Scientific launches Promus and Taxus stents in India
Boston Scientific Corp. (NYSE:BSX) is planting its flag in the Republic of India, one of the world’s fastest-growing healthcare markets.
The Natick, Mass.-based medical device giant said it’s launching the third generation of its market- leading Promus and Taxus drug-eluting stents in a country of more than 1.1 billion people. Company officials say the DES market in India is surging, with an estimated 150,000 stents implanted annually. BSX won regulatory approval for the devices in India last year.
Australia releases regulatory update for in vitro devices
By Stewart Eisenhart, Emergo Group
The Therapeutic Goods Administration (TGA), Australia’s medical device regulator, has specified which in vitro devices (IVDs) will be required to undergo application audits.
According to Australia’s Therapeutic Goods (Regulations) 2002, eight types of IVDs fall under the application audit requirements:
Medtronic’s Irish subsidiary sees green
The Emerald Isle was good to Medtronic last year.
Medtronic Vascular Galway Ltd., the Irish subsidiary of Medtronic Inc. (NYSE:MDT), posted a $269 million (USD) profit on more than $1 billion in sales during 2010, according to a report in the Irish Times.
The subsidiary, which Medtronic acquired in 2009 when it bought out another subsidiary, Medtronic Vascular Holdings, employs 1,850 employees in Galway, according to the newspaper.
Cappella closes $14.3 million round | Funding roundup
Here’s a roundup of the latest dealflow and investment news:
WEST taps Ilene Fischer for executive director | Personnel moves
Here’s the latest personnel changes from medical device, diagnostics and life science companies around the nation. For more recent hirings and firings, check out MassDevice’s compilation of the latest personnel moves.
Study: Stryker knee, hip implants have lowest revision rates | Research roundup
Here’s a roundup of recent clinical trial and scientific study news: